Navigating Virtual Prescribing Policy Changes in 2025
A practitioner perspective by Dr. Tom Milam, Chief Medical Officer, Iris Telehealth.
The argument
Telehealth prescribing has expanded access, especially for addiction treatment and rural patients, but DEA flexibility expirations create dangerous uncertainty. Regulators, providers, and patients must collaborate on permanent frameworks that keep virtual prescribing accessible while protecting safety.
Why we picked it
The HTC editorial desk curates practitioner perspectives that pass a simple test: would a health system executive, product leader, or investor act differently after reading it? This piece by Dr. Tom Milam earns its place - it comes from the operating trenches of policy & regulation, not the conference stage, and it takes a position specific enough to disagree with.
The bigger picture
The AI adoption question runs through every executive conversation in 2026. The evidence base is finally arriving: the largest controlled study of ambient documentation, published in JAMA, found clinicians saved 16 minutes of documentation time per day - but only a third of users hit the usage threshold for maximum benefit (our coverage). Meanwhile Rock Health has stopped labeling AI as a differentiator at all, because every company claims it - which is exactly why operating discipline of the kind described here separates winners from demo-ware.
Read it alongside our own reporting in Policy & Regulation, where the data behind this debate is covered daily on the HTC Wire.